Cerity Partners
NKTR icon

Cerity Partners’s Nektar Therapeutics NKTR Stock Holding History

Cerity Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,061
Closed -$51.6K – 2721
2025
Q1 		$51.6K Buy
+5,061
New +$66.1K ﹤0.01% 2396
2019
Q3 		– Sell
-450
Closed -$240K – 497
2019
Q2 		$240K Buy
450
+53
+13% +$26.6K 0.02% 427
2019
Q1 		$200K Sell
397
-78
-16% -$46.2K 0.01% 506
2018
Q4 		$234K Buy
+475
New +$287K 0.02% 449

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cerity Partners's NKTR Position: Q2 2025 in Review

Cerity Partners sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 5,061 shares — an estimated $51.6K sold.

Cerity Partners first reported a position in NKTR in Q4 2018 and held it in 4 quarters. The position peaked at $240K in Q2 2019. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Cerity Partners reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cerity Partners sold 5,061 Nektar Therapeutics shares in Q2 2025, an estimated $51.6K.
  • Cerity Partners first reported a position in Nektar Therapeutics in Q4 2018 and held it in 4 quarters.
  • Cerity Partners's Nektar Therapeutics position peaked at $240K in Q2 2019.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Cerity Partners's 13F filing for Q2 2025, filed 13 Aug 2025.